David Taber to Antiviral Agents
This is a "connection" page, showing publications David Taber has written about Antiviral Agents.
Connection Strength
0.688
-
Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004 Sep; 6(3):101-9.
Score: 0.203
-
Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Transpl Infect Dis. 2017 Dec; 19(6).
Score: 0.127
-
Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation. J Pharm Pract. 2016 Apr; 29(2):97-102.
Score: 0.101
-
Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis. 2013 Dec; 15(6):551-8.
Score: 0.095
-
Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol. 2012 Jun; 7(6):1003-9.
Score: 0.086
-
Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation. 2010 May 27; 89(10):1218-23.
Score: 0.076